Dana Barchel

Dana Barchel

Auto-generated profile, based on publicly available information

Dana Barchel

Clinical Pharmacology and Toxicology Unit, Faculty of Medical & Health Sciences, Shamir Medical Center (Assaf Harofeh), Tel Aviv University, Zerifin, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
MSMiriam Shteinshnaider
Miriam Shteinshnaider
DBDana Barchel
Dana Barchel
DADorit Almoznino-Sarafian
Dorit Almoznino-Sarafian
ITIrma Tzur
Irma Tzur
NTNeli Tsatsanashvili
Neli Tsatsanashvili
OGOleg Gorelik
Oleg Gorelik

1 February 2024 in Cannabis & Cannabinoid Research
Verified
Journal Article
Closed access
DBDana Barchel
Dana Barchel
OSOrit Stolar
Orit Stolar
TZTomer Ziv-Baran
Tomer Ziv-Baran
IGItai Gueta
Itai Gueta
MBMatitiahu Berkovitch
Matitiahu Berkovitch
LSLihi Bar-Lev Schleider
Lihi Bar-Lev Schleider
Objective: Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed. The aim of this study was to describe the experience of patients with TS with medical cannabis. Materials and Methods: TS patients were recruited from a registry of patients (“Tikun Olam” company). Questionnaires were answered before and after 6 months of treatment. Patients were divided into two groups: (A) patients who responded and (B) patients who did not respond to the follow-up questionnaire. In group A, an analysis was made to evaluate the presence and frequency of motor and vocal tics. The patients' general mood, employment status, quality of life, and comorbidities were also included in the analysis. Results: Seventy patients were identified. The tetrahydrocannabinol and cannabidiol mean daily dose was 123 and 50.5 mg, respectively. In group A, a statistically significant improvement was identified in quality of life ( p <0.005), employment status ( p =0.027), and in the reduction of the number of medications ( p 0.999), tics frequency ( p =0.062), or general mood ( p =0.129). The most frequent adverse effects were dizziness ( n =4) and increased appetite ( n =3). Conclusion: Subjective reports from TS patients suggest that medical cannabis may improve their quality of life and comorbidities. More studies are needed to evaluate the efficacy and safety of medical cannabis. Registry in the MOH: https://www.moh.gov.sg/ (Trial number: 0185-19-ASF)

5 March 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
IGItai Gueta
Itai Gueta
ABAdi Braun
Adi Braun
AGAdi Gilan
Adi Gilan
MBMaya Berlin
Maya Berlin
EKElkana Kohn
Elkana Kohn
RLRonen Loebstein
Ronen Loebstein

5 January 2026 in Current Neuropharmacology
Verified
Journal Article
Closed access
BDBarchel Dana
Barchel Dana
KEKohn Elkana
Kohn Elkana
HAHazan Ariela
Hazan Ariela
BMBerkovitch Matitiahu
Berkovitch Matitiahu
BIBabarashvili Ilia
Babarashvili Ilia
SOStolar Orit
Stolar Orit
Introduction: Medical cannabis has gained growing attention as a potential treatment for children with Autism Spectrum Disorder (ASD), particularly in cases where conventional pharmacological approaches have proven ineffective. Emerging evidence suggests that cannabinoid-based therapies may alleviate Attention Deficit Hyperactivity Disorder (ADHD) related symptoms in children with ASD. The objective of this study is to evaluate changes in ADHD symptoms over six months of treatment with a CBD-rich cannabis oil, using the Conners' Teacher Rating Scale as the assessment tool. Methods: This was a prospective, single-arm, open-label study conducted at a single center. A total of 109 children and young adults diagnosed with ASD and ADHD symptoms were recruited between November 2019 and April 2021. Of these, 53 participants were assessed by their schoolteachers using the Conners' Teacher Rating Scale (CTRS) questionnaire, both before and after a three- to sixmonth treatment period with a CBD-rich, cannabis oil-based product. Blood samples were collected before and after treatment to measure cannabinoid levels, including CBD, 6-OH-CBD, 7-COOHCBD, and 7-OH-CBD. Results: Significant improvements were observed in the following categories: anxious-shyness, perfectionism, ADHD index, emotional lability, and hyperactivity-impulsivity (p < 0.001). Additional trends toward improvement were identified in oppositional behavior (p = 0.009), cognitive inattention (p = 0.009), hyperactivity (p = 0.006), the Conners’ Global Index (p = 0.007), and DSM-IV inattention scores (p = 0.003). No significant correlations were found between cannabinoid dosage or blood levels and changes in CTRS scores, except for emotional lability, where higher CBD concentrations were predictive of greater symptom improvement. Discussion: This is the first prospective study to evaluate the effects of CBD-rich cannabis on ADHD symptoms in children with ASD using standardized teacher-based Assessments (CTRS). The findings indicate improvements in core behavioral domains. While previous studies have focused primarily on parent-reported outcomes or small-scale trials, our results support emerging evidence on the role of cannabinoids in modulating attention and emotional regulation. The main limitations of the study were its open-label design. Conclusion: CBD-rich cannabis oil may reduce ADHD symptoms in children with ASD. These findings support the need for future clinical trials to validate efficacy and determine optimal dosing.

27 July 2026 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
IAIbrahim Abu-Kishk
Ibrahim Abu-Kishk
RHRana Hajyahia
Rana Hajyahia
YWYifat Wiener
Yifat Wiener
RCRana Cohen
Rana Cohen
GKGideon Koren
Gideon Koren
DBDana Barchel
Dana Barchel
Background: Nausea and vomiting in pregnancy (NVP) can substantially affect maternal well-being and quality of life. Cultural, social, and healthcare-system factors may influence healthcare-seeking behavior and management strategies. The primary objective of this study was to compare the proportion of Arab and non-Arab women who sought medical consultation for NVP. Secondary objectives were to assess differences in NVP duration and impact on quality of life, explore sources of advice and support, characterize recommendations for NVP management, and investigate reasons for not seeking medical consultation. Methods: This cross-sectional study was conducted in the maternity ward of Shamir (Assaf Harofeh) Medical Center between January and October 2018. Postpartum women who reported NVP during their most recent pregnancy were interviewed using a structured questionnaire available in Hebrew and Arabic. Group comparisons were performed using Chi-square, Fisher’s exact, t-tests, or Mann–Whitney U tests, as appropriate. Multivariable logistic regression was used to identify factors independently associated with seeking medical consultation. Results: A total of 190 women were included (126 non-Arab and 64 Arab). Overall, 92 non-Arab women (73.0%) sought medical consultation for NVP compared with 30 Arab women (46.9%) ( p < 0.001). In the multivariable analysis, non-Arab ethnicity was independently associated with seeking medical consultation (OR = 2.64, 95% CI: 1.06–6.58; p = 0.036). Arab women reported greater NVP-related impairment in quality of life and daily functioning ( p = 0.035) and were more likely to rely on family members for advice (45.3% vs. 28.6%, p = 0.022). Dietary modifications were recommended more frequently to Arab women ( p = 0.023). No significant differences were observed between the groups regarding reasons for not seeking medical consultation. Conclusions: Significant differences were observed between Arab and non-Arab women in the perception and management of NVP. Arab women reported a greater impact of NVP on quality of life and were less likely to seek medical consultation, whereas non-Arab women more frequently sought professional care. Although ethnicity remained independently associated with healthcare-seeking behavior, the observed differences are likely influenced by a complex interplay of demographic, socioeconomic, cultural, behavioral, and healthcare-system-related factors. These findings highlight the importance of accessible, culturally sensitive, and patient-centered counseling to support equitable management of NVP.